European Healthcare Acquisition & Growth Company B.V.

European Healthcare Acquisition & Growth Company B.V.

EHCS.AS
European Healthcare Acquisition & Growth Company B.V.NL flagEuronext Amsterdam
9.10
EUR
- -
- -
71.94MMarket Cap
European Healthcare Acquisition & Growth Company B.V.
EHCS.AS
(Euronext Amsterdam)

Recent

price

9.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
FRC
- -
- -
- -
Revenue per Share
-1.51
-4.51
- -
Basic EPS, GAAP
0.35
-0.48
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
-1.47
-4.88
- -
Book Value per Share
2.57
-3.69
- -
Tangible Book Value per Share
2
7
- -
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
-3
-30
26
Net Income, GAAP
- -
- -
0.81
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
206
-25
2
Working Capital
- -
- -
- -
LT Debt
4
-25
2
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
-183.13
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-107.73%
Free Cash Flow
- -
- -
-38.79%
Net Income, GAAP
- -
- -
-188%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-1.51
2022
- -
- -
- -
- -
-4.51
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Business
European Healthcare Acquisition & Growth Company B.V. (EHCS.AS) operates as a blank-check special purpose acquisition company focused on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more operating businesses primarily in the European healthcare sector; it targets subsectors including biotechnology and specialty pharma, pharma services, medical technology and medical devices, diagnostic and lab services, bioinformatics, and life science tools. Incorporated in 2021 and headquartered at Theresienhöhe 28, 80339 Munich, Germany, the company serves as the first operators-led, healthcare-focused acquisition vehicle in Europe, leveraging management expertise to identify and integrate targets across these therapeutic and technology-driven areas. Geographically, it concentrates on companies with principal operations in Europe, providing a structured framework for investors seeking exposure to high-growth healthcare opportunities through sponsored SPAC investments. In recent developments, the company announced its dissolution in November 2024, with delisting from Euronext Amsterdam following the expiry of its acquisition mandate without completing a business combination; it also reported a CEO change in May 2024, published its half-year results in September 2024, and held its final annual general meeting in June 2024 ahead of liquidation proceedings.